HIMS · Hims & Hers Health, Inc.
$32.70
-0.14 (-0.43%)
At close · Jul 20
Market Cap
$7.57B
Shares
231.46M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$2.35B
+59%
FY2025
Net Income
$128.37M
+1.8%
FY2025
Gross Margin
73.84%
-5.6pp
FY2025
Operating Margin
4.5%
+0.3pp
FY2025
Diluted EPS
$0.51
-3.8%
FY2025
Operating Cash Flow
$300.01M
+19.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|
| $2.8B – $3B | $2.37B | $2.35B | $1.48B | $872M | $526.92M | $271.88M | $148.76M | $82.56M | |
| — | $670.26M | $614.26M | $303.38M | $157.05M | $118.19M | $67.38M | $39.31M | $37.95M | |
| — | $1.7B | $1.73B | $1.17B | $714.95M | $408.72M | $204.49M | $109.45M | $44.61M | |
| — | — | 73.84% | 79.45% | 81.99% | 77.57% | 75.22% | 73.58% | 54.03% | |
| — | $333.78M | $272.72M | $167.77M | $129.88M | $98.19M | $113.66M | $26.03M | — | |
| — | $175.65M | — | — | — | — | $183.63M | $65.61M | $55.86M | |
| — | $34.1M | $23.7M | $3.8M | $3.5M | $4.1M | $2.1M | $100K | $100K | |
| — | — | $54.5M | $17.09M | $9.52M | $7.47M | $4.08M | $1.06M | $260K | |
| — | $1.73B | $1.63B | $1.11B | $744.4M | $477.42M | $319.54M | $124.59M | $119.02M | |
| — | -$30.61M | $105.61M | $61.9M | -$29.45M | -$68.7M | -$115.04M | -$15.14M | -$74.41M | |
| — | — | 4.5% | 4.19% | -3.38% | -13.04% | -42.31% | -10.18% | -90.14% | |
| — | — | $160.12M | $78.99M | -$19.94M | -$61.22M | -$110.97M | -$14.09M | -$74.15M | |
| — | — | — | — | — | — | $0 | $10K | $369K | |
| — | — | — | — | — | — | — | $3M | — | |
| — | -$7.52M | $18.31M | $9.81M | $7.88M | $2.99M | $4.25M | -$2.84M | $2.44M | |
| — | -$38.12M | $123.92M | $71.71M | -$21.57M | -$65.71M | -$110.8M | -$17.99M | -$71.97M | |
| — | -$24.89M | -$4.44M | -$54.33M | $1.98M | -$31K | -$3.14M | $127K | $90K | |
| — | -$13.24M | $128.37M | $126.04M | -$23.55M | -$65.68M | -$107.66M | -$18.11M | -$72.06M | |
| — | — | 5.47% | 8.54% | -2.7% | -12.46% | -39.6% | -12.18% | -87.29% | |
| — | -$17.48M | $130.98M | $125.84M | -$23.39M | -$65.82M | -$107.79M | -$18.13M | -$72.06M | |
| USD/shares | — | — | $0.57 | $0.58 | -$0.11 | -$0.32 | -$0.58 | -$0.51 | -$2.07 |
| USD/shares | — | — | $0.51 | $0.53 | -$0.11 | -$0.32 | -$0.58 | -$0.51 | -$2.07 |
| shares | — | — | 224.96M | 215.94M | 209.34M | 204.52M | 186.78M | 35.35M | 34.76M |
| shares | — | — | 258.23M | 236.81M | 209.34M | 204.52M | 186.78M | 35.35M | 34.76M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2025: $175M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Drug Manufacturers - Specialty & Generic median 2.24×
EV/EBIT
—
Drug Manufacturers - Specialty & Generic median 34.94×
P/E (TTM)
—
Drug Manufacturers - Specialty & Generic median 20.52×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| United States | $2,213,648,000 | $1,449,671,000 | $854,494,000 |
| Non Us | $133,989,000 | $26,843,000 | $17,506,000 |
Key facts
CIK
1773751
CUSIP
433000106
13F (30d)
41 filings
40 filers
Visit website
Investor relations